A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL, GROUP-SEQUENTIAL,
PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF
INTRAVENOUS GAMMAGARD LIQUID (IMMUNE GLOBULIN INFUSION, 10%) FOR
PRIMARY INFECTION PROPHYLAXIS COMPARED WITH SECONDARY INFECTION
PROPHYLAXIS IN ADULT SUBJECTS WITH MULTIPLE MYELOMA RECEIVING B-CELL
MATURATION ANTIGEN×CD3¿DIRECTED BISPECIFIC ANTIBODY THERAPY
- Registry ID
- TAK-339-3001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- TAKEDA DEVELOPMENT CENTER AMERICAS INC
- Start date
- 2026-04-16
- Last update
- 2025-07-16
Conditions
Related clinical trials
- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- PHASE I DOSE ESCALATION STUDY OF LIPOSOMAL CURCUMIN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY
AND SAFETY OF BMS-986393, A GPRC5D-DIRECTED CAR-T CELL THERAPY, VERSUS
STANDARD REGIMENS IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY AND
LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
- [68GA]GA-PENTIXAFOR (CXCR4) PET/MR FOR INITIAL STAGING AND FOLLOW UP IN MULTIPLE MYELOMA: PROSPECTIVE COMPARISON WITH STANDARD OF CARE PET/CT AND EVALUATION OF THERAPY INFLUENCE
- A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL TO COMPARE THE EFFICACY AND SAFETY OF IDECABTAGENE VICLEUCEL
WITH LENALIDOMIDE MAINTENANCE VERSUS LENALIDOMIDE MAINTENANCE THERAPY ALONE IN ADULT PARTICIPANTS WITH
NEWLY DIAGNOSED MULTIPLE MYELOMA WHO HAVE SUBOPTIMAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
(KARMMA-9).
- LORATADINE FOR THE PREVENTION OF BONE PAIN CAUSED BY GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) DURING STEM CELL MOBILIZATION
View on source registry